348 related articles for article (PubMed ID: 31209238)
1. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Menden MP; Wang D; Mason MJ; Szalai B; Bulusu KC; Guan Y; Yu T; Kang J; Jeon M; Wolfinger R; Nguyen T; Zaslavskiy M; ; Jang IS; Ghazoui Z; Ahsen ME; Vogel R; Neto EC; Norman T; Tang EKY; Garnett MJ; Veroli GYD; Fawell S; Stolovitzky G; Guinney J; Dry JR; Saez-Rodriguez J
Nat Commun; 2019 Jun; 10(1):2674. PubMed ID: 31209238
[TBL] [Abstract][Full Text] [Related]
2. Network Propagation Predicts Drug Synergy in Cancers.
Li H; Li T; Quang D; Guan Y
Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
[TBL] [Abstract][Full Text] [Related]
3. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.
Regan-Fendt KE; Xu J; DiVincenzo M; Duggan MC; Shakya R; Na R; Carson WE; Payne PRO; Li F
NPJ Syst Biol Appl; 2019; 5():6. PubMed ID: 30820351
[TBL] [Abstract][Full Text] [Related]
4. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
5. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
6. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
[TBL] [Abstract][Full Text] [Related]
7. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
Sharma A; Rani R
J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
[TBL] [Abstract][Full Text] [Related]
9. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
10. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
[TBL] [Abstract][Full Text] [Related]
11. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
13. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract][Full Text] [Related]
14. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Schwartzberg LS; Vidal GA
Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
[TBL] [Abstract][Full Text] [Related]
15. SNSynergy: Similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations.
Huangfu X; Zhang C; Li H; Li S; Li Y
Comput Biol Chem; 2024 Jun; 110():108054. PubMed ID: 38522389
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Drug Combination Prediction by Integrating Multiomics Data in Deep Learning Models.
Zhang T; Zhang L; Payne PRO; Li F
Methods Mol Biol; 2021; 2194():223-238. PubMed ID: 32926369
[TBL] [Abstract][Full Text] [Related]
17. A simple gene set-based method accurately predicts the synergy of drug pairs.
Hsu YC; Chiu YC; Chen Y; Hsiao TH; Chuang EY
BMC Syst Biol; 2016 Aug; 10 Suppl 3(Suppl 3):66. PubMed ID: 27585722
[TBL] [Abstract][Full Text] [Related]
18. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
Amzallag A; Ramaswamy S; Benes CH
BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
[TBL] [Abstract][Full Text] [Related]
19. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
[TBL] [Abstract][Full Text] [Related]
20. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
Jiang P; Lee W; Li X; Johnson C; Liu JS; Brown M; Aster JC; Liu XS
Cell Syst; 2018 Mar; 6(3):343-354.e5. PubMed ID: 29428415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
